Introduction Chronic Kidney Disease (CKD) represents a growing global health challenge, affecting approximately 850 million individuals worldwide. The silent nature of this disease is one of its most dangerous features, as nearly 90% of affected individuals remain undiagnosed, leading to lost opportunities for early intervention and progression toward end-stage renal failure. In this context, artificial intelligence (AI) emerges as a transformative tool capable of bringing about a qualitative leap in diagnostic speed and predictive accuracy, directly contributing to saving patients’ lives and reducing health and economic burdens. First: Traditional Challenges in Diagnosing Chronic Kidney Disease Traditional methods for diagnosing CKD rely on static biomarkers such as estimated glomerular filtration rate (eGFR) and linear risk equations such as the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation and the Kidney Failure Risk Equation (KFRE). These tools face fundamental limitations, including limited sensitivity in early detection, inability to identify patients with rapid progression in the early stages, and poor generalizability across different population groups. In addition, manual assessment and documentation consume about 37% of a physician’s workday, limiting the time available for direct care and leading to missed critical cases. The literature indicates that nearly 60% of CKD cases remain undiagnosed, reflecting a huge diagnostic gap that requires innovative solutions. Second: How Does AI Enhance Diagnostic Speed? 1. Integration of Multimodal Data and High-Dimensional Analysis The core advantage of AI lies in its ability to integrate and analyze multimodal data, including electronic health records, medical imaging, genetic data, and wearable devices, going beyond the limits of static biomarkers. AI-based models demonstrate improved discriminative ability compared with traditional statistical methods, especially when integrating longitudinal trajectories and multimodal inputs. 2. Early Detection Through Deep Learning Models Deep learning models achieve classification accuracy ranging between 85% and 99% in detecting CKD, depending on data quality and homogeneity of patient cohorts. A recent study has shown the possibility of detecting CKD by analyzing echocardiography videos using AI, opening new horizons for non-invasive screening in various clinical settings. 3. Predicting the Risk of Progression to Kidney Failure Area under the curve (AUC) values in AI models for predicting outcomes such as end-stage kidney disease reach 0.85–0.96. These models outperform traditional tools in identifying patients at risk of rapid progression, enabling more effective early therapeutic interventions. 4. Specific Clinical Applications Demonstrating Effectiveness In a study involving 341 patients, an AI system configured according to KDIGO guidelines achieved a sensitivity of 97% and accuracy of 85% in identifying patients with confirmed CKD, and a sensitivity of 87% and accuracy of 87% in identifying at-risk patients. Deep learning models for total kidney volume segmentation in polycystic kidney disease also demonstrate performance superior to human experts, reducing manual segmentation time from 56 minutes to only 8.5 minutes. Third: The Role of AI in Saving Patients’ Lives 1. Moving from Reactive Care to Predictive Care AI models bring about a fundamental shift in the renal care model, from a reactive approach based on static data to a predictive model that uses continuous physiological monitoring, dynamic risk recalibration, and individualized prediction. This shift allows early intervention before acute deterioration in kidney function occurs, saving the lives of patients who would otherwise be detected at late stages. 2. Improving Clinical Decisions in Intensive Care Units Deep learning models demonstrate the ability to predict acute kidney injury (AKI) in intensive care units, allowing medical teams to take immediate preventive measures. Models for predicting hypotension during dialysis achieve AUROC values ranging between 0.89 and 0.95, reducing potentially serious complications. 3. Improving Personalized Treatment Strategies AI enables the identification of precise patient phenotypes, guiding targeted interventions such as treatment with sodium-glucose cotransporter-2 (SGLT2) inhibitors and optimizing the timing of dialysis initiation. This personalization cعontributes to improving clinical outcomes and reducing mortality rates. By the Head of the Department, Prof. Dr. Younis Abdul Ridha Al-Khafaji AL_mustaqbal University is the first university in Iraq